Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

Publication

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

Journal Paper/Review - Jul 11, 2023

König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos

Citation

König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.

Type

Journal Paper/Review (English)

Journal

ESMO Open 2023; 8

Publication Date

Jul 11, 2023

Issn Electronic

2059-7029

Pages

101595

Brief description/objective

The inclusion of immune checkpoint inhibitors (ICIs) in the treatment of operable stage III non-small-cell lung cancer is becoming a new standard. Programmed death-ligand 1 (PD-L1) protein expression on tumor cells has emerged as the most important biomarker for sensitivity to ICIs targeting the programmed cell death protein 1 (PD-1)-PD-L1 axis. Little is known about the impact of neoadjuvant treatment on PD-L1 expression.